Your browser doesn't support javascript.
loading
Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.
Jaramillo, Sonia; Krisam, Johannes; Le Cornet, Lucian; Kratzmann, Markus; Baumann, Lukas; Eissymont, Olga; Crysandt, Martina; Görner, Martin; Kayser, Sabine; Krause, Stefan; Schliemann, Christoph; Gaska, Tobias; Kaufmann, Martin; Chemnitz, Jens; Schaich, Markus; Hoellein, Alexander; Platzbecker, Uwe; Kieser, Meinhard; Müller-Tidow, Carsten; Schlenk, Richard F.
Afiliación
  • Jaramillo S; Department of Internal Medicine V, Heidelberg University Hospital.
  • Krisam J; Institute of Medical Biometry, University of Heidelberg.
  • Le Cornet L; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center.
  • Kratzmann M; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center.
  • Baumann L; Institute of Medical Biometry, University of Heidelberg.
  • Eissymont O; Institute of Medical Biometry, University of Heidelberg.
  • Crysandt M; Department of Medicine IV, Aachen University Hospital, Aachen.
  • Görner M; Department of Hematology, Oncology and Palliative Medicine, Community Hospital Bielefeld.
  • Kayser S; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Germany; Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University; Department of Medicine I - Hematology and Cell Therapy, University Hospit
  • Krause S; Department of Medicine V, Erlangen University Hospital.
  • Schliemann C; Department of Medicine A, Münster University Hospital.
  • Gaska T; Department of Hematology and Oncology, St. Josef Brothers' Hospital Paderborn.
  • Kaufmann M; Department of Hematology, Oncology and Palliative Medicine, Robert-Bosch Hospital Stuttgart.
  • Chemnitz J; Department of Internal Medicine, Hematology, Oncology and Palliative Medicine, Prot. Monastery Hospital St. Jakob Koblenz.
  • Schaich M; Department of Hematology, Oncology and Palliative Medicine, Winnenden Hospital, Winnenden.
  • Hoellein A; Department of Internal Medicine III - Hematology and Oncology, Red Cross Hospital Munich, Munich.
  • Platzbecker U; Department of Medicine I - Hematology and Cell Therapy, University Hospital Leipzig.
  • Kieser M; Institute of Medical Biometry, University of Heidelberg.
  • Müller-Tidow C; Department of Internal Medicine V, Heidelberg University Hospital.
  • Schlenk RF; Department of Internal Medicine V, Heidelberg University Hospital, Germany; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center.
Haematologica ; 109(6): 1973-1976, 2024 06 01.
Article en En | MEDLINE | ID: mdl-38385304
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Gemtuzumab / Aminoglicósidos Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2024 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Gemtuzumab / Aminoglicósidos Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2024 Tipo del documento: Article